

Martin KÄjbel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5561425/publications.pdf>

Version: 2024-02-01

216
papers

14,428
citations

17440

63
h-index

23533

111
g-index

227
all docs

227
docs citations

227
times ranked

14126
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary. <i>New England Journal of Medicine</i> , 2009, 360, 2719-2729.	27.0	706
2	Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies. <i>PLoS Medicine</i> , 2008, 5, e232.	8.4	675
3	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. <i>Journal of Clinical Investigation</i> , 2013, 123, 517-25.	8.2	462
4	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
5	Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors. <i>PLoS ONE</i> , 2009, 4, e6412.	2.5	354
6	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , The, 2013, 14, 853-862.	10.7	335
7	Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 203-211.	1.4	332
8	Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. <i>Journal of the National Cancer Institute</i> , 2019, 111, 60-68.	6.3	319
9	Optimized p53 immunohistochemistry is an accurate predictor of <i>TP53</i> mutation in ovarian carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 247-258.	3.0	280
10	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	7.1	260
11	Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. <i>Human Pathology</i> , 2008, 39, 1239-1251.	2.0	231
12	Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. <i>International Journal of Gynecological Pathology</i> , 2019, 38, S123-S131.	1.4	226
13	Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010. <i>Gynecologic Oncology</i> , 2011, 121, 407-415.	1.4	225
14	A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. <i>American Journal of Surgical Pathology</i> , 2009, 33, 14-21.	3.7	211
15	Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. <i>Cancer</i> , 2003, 97, 2978-2987.	4.1	197
16	Expression of Cyclooxygenase 2 Is an Independent Prognostic Factor in Human Ovarian Carcinoma. <i>American Journal of Pathology</i> , 2002, 160, 893-903.	3.8	183
17	The Fallopian Tube: Primary Site of Most Pelvic High-grade Serous Carcinomas. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 58-64.	2.5	181
18	Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. <i>Modern Pathology</i> , 2015, 28, 505-514.	5.5	180

#	ARTICLE	IF	CITATIONS
19	An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 430-441.	1.4	180
20	HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. <i>BMC Cancer</i> , 2009, 9, 433.	2.6	175
21	Reproducibility of histological cell type in high-grade endometrial carcinoma. <i>Modern Pathology</i> , 2013, 26, 1594-1604.	5.5	167
22	p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. <i>Journal of Pathology</i> , 2020, 250, 336-345.	4.5	164
23	POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. <i>Gynecologic Oncology</i> , 2014, 134, 15-19.	1.4	159
24	Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas. <i>Neoplasia</i> , 2008, 10, 1021-1027.	5.3	158
25	Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. <i>British Journal of Cancer</i> , 2004, 90, 815-821.	6.4	157
26	Overexpression of the Embryonic-Lethal Abnormal Vision-like Protein HuR in Ovarian Carcinoma Is a Prognostic Factor and Is Associated with Increased Cyclooxygenase 2 Expression. <i>Cancer Research</i> , 2004, 64, 189-195.	0.9	153
27	Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. <i>Gynecologic Oncology</i> , 2016, 143, 46-53.	1.4	153
28	BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2012, 25, 740-750.	5.5	151
29	High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 343-350.	1.4	146
30	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	12.8	144
31	Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible. <i>American Journal of Surgical Pathology</i> , 2010, 34, 984-993.	3.7	143
32	The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. <i>Journal of Pathology</i> , 2010, 222, 191-198.	4.5	136
33	Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. <i>Modern Pathology</i> , 2017, 30, 577-586.	5.5	132
34	Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. <i>Gynecologic Oncology</i> , 2010, 116, 50-56.	1.4	129
35	Morphologic Spectrum of Immunohistochemically Characterized Clear Cell Carcinoma of the Ovary. <i>American Journal of Surgical Pathology</i> , 2011, 35, 36-44.	3.7	129
36	Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. <i>Lancet Oncology</i> , The, 2011, 12, 1071-1080.	10.7	127

#	ARTICLE	IF	CITATIONS
37	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. <i>Modern Pathology</i> , 2009, 22, 469-475.	5.5	125
38	Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. <i>Modern Pathology</i> , 2016, 29, 302-314.	5.5	123
39	Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1421-1432.	3.7	115
40	The molecular origin and taxonomy of mucinous ovarian carcinoma. <i>Nature Communications</i> , 2019, 10, 3935.	12.8	110
41	Oncogenic mutations in histologically normal endometrium: the new normal?. <i>Journal of Pathology</i> , 2019, 249, 173-181.	4.5	106
42	Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. <i>Histopathology</i> , 2014, 64, 1004-1013.	2.9	104
43	Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases. <i>American Journal of Surgical Pathology</i> , 2015, 39, 357-364.	3.7	104
44	Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma. <i>Oncogene</i> , 2007, 26, 7584-7589.	5.9	101
45	PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. <i>Gynecologic Oncology</i> , 2013, 128, 409-414.	1.4	99
46	Calculator for ovarian carcinoma subtype prediction. <i>Modern Pathology</i> , 2011, 24, 512-521.	5.5	95
47	Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. <i>Journal of Translational Medicine</i> , 2012, 10, 33.	4.4	93
48	Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. <i>Journal of Pathology</i> , 2010, 220, 392-400.	4.5	92
49	Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. <i>Oncogene</i> , 2003, 22, 8653-8661.	5.9	90
50	Primary Ovarian Mucinous Carcinoma of Intestinal Type: Significance of Pattern of Invasion and Immunohistochemical Expression Profile in a Series of 31 Cases. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 99-107.	1.4	90
51	Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. <i>Modern Pathology</i> , 2016, 29, 1586-1593.	5.5	87
52	Efficient molecular subtype classification of high-grade serous ovarian cancer. <i>Journal of Pathology</i> , 2015, 236, 272-277.	4.5	81
53	Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. <i>American Journal of Surgical Pathology</i> , 2017, 41, 245-252.	3.7	81
54	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 569-580.	7.0	79

#	ARTICLE	IF	CITATIONS
55	Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins. <i>American Journal of Surgical Pathology</i> , 2018, 42, 76-83.	3.7	78
56	Targeted mutation analysis of endometrial clear cell carcinoma. <i>Histopathology</i> , 2015, 66, 664-674.	2.9	77
57	Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas. <i>Histopathology</i> , 2016, 69, 288-297.	2.9	77
58	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. <i>British Journal of Cancer</i> , 2014, 111, 2297-2307.	6.4	76
59	Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1677-1686.	2.5	70
60	Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1548-1557.	3.7	70
61	Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary. <i>American Journal of Surgical Pathology</i> , 2017, 41, 685-695.	3.7	70
62	Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 279-293.	3.0	70
63	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 250-261.	3.0	70
64	Immunohistochemical characterization of prototypical endometrial clear cell carcinoma's diagnostic utility of HNF1 β and oestrogen receptor. <i>Histopathology</i> , 2014, 64, 585-596.	2.9	68
65	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. <i>BMC Cancer</i> , 2018, 18, 347.	2.6	67
66	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2015, 6, 39088-39097.	1.8	67
67	Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy. <i>Histopathology</i> , 2016, 68, 916-924.	2.9	65
68	Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. <i>Annals of Oncology</i> , 2011, 22, 341-347.	1.2	64
69	Quantification of ER/PR expression in ovarian low-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2013, 128, 371-376.	1.4	63
70	Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. <i>Cancer</i> , 2021, 127, 2409-2422.	4.1	62
71	Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 456-464.	2.8	61
72	Ezrin Promotes Ovarian Carcinoma Cell Invasion and Its Retained Expression Predicts Poor Prognosis in Ovarian Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2006, 25, 121-130.	1.4	59

#	ARTICLE	IF	CITATIONS
73	Adult-Type Granulosa Cell Tumors and FOXL2 Mutation. <i>Cancer Research</i> , 2009, 69, 9160-9162.	0.9	58
74	<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. <i>Cancer Research</i> , 2017, 77, 4268-4278.	0.9	56
75	Immunophenotypic features of dedifferentiated endometrial carcinoma – insights from BRG1/INI1-deficient tumours. <i>Histopathology</i> , 2016, 69, 560-569.	2.9	54
76	Immunohistochemical Profiling of Endometrial Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 128-139.	1.4	54
77	Histotype classification of ovarian carcinoma: A comparison of approaches. <i>Gynecologic Oncology</i> , 2018, 151, 53-60.	1.4	54
78	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. <i>Modern Pathology</i> , 2019, 32, 1834-1846.	5.5	54
79	Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. <i>Journal of Pathology</i> , 2021, 253, 41-54.	4.5	54
80	Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. <i>Modern Pathology</i> , 2006, 19, 581-587.	5.5	52
81	Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. <i>BMC Medicine</i> , 2007, 5, 33.	5.5	52
82	The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. <i>Modern Pathology</i> , 2013, 26, 1255-1263.	5.5	52
83	Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases. <i>American Journal of Surgical Pathology</i> , 2016, 40, 166-180.	3.7	51
84	The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 239-252.	3.3	50
85	Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high risk endometrial cancers. <i>Gynecologic Oncology</i> , 2015, 139, 268-274.	1.4	50
86	MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. <i>Gynecologic Oncology</i> , 2013, 131, 309-314.	1.4	49
87	Therapeutic options for mucinous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 552-560.	1.4	49
88	Critical molecular abnormalities in high-grade serous carcinoma of the ovary. <i>Expert Reviews in Molecular Medicine</i> , 2008, 10, e22.	3.9	48
89	ALK Is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1353-1359.	3.7	48
90	Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 353-362.	1.4	45

#	ARTICLE	IF	CITATIONS
91	Endometrial Carcinomas With Clear Cells. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 323-333.	1.4	44
92	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	7.0	43
93	Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 140, 124-130.	1.4	42
94	Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5400-5410.	7.0	41
95	Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 555-561.	1.4	40
96	Loss of switch/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas. <i>Histopathology</i> , 2020, 77, 46-54.	2.9	39
97	<scp>SWI</scp>/<scp>SNF</scp>-deficiency defines highly aggressive undifferentiated endometrial carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 144-153.	3.0	38
98	The Evolution of Ovarian Carcinoma Subclassification. <i>Cancers</i> , 2022, 14, 416.	3.7	38
99	Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer. <i>PLoS ONE</i> , 2008, 3, e3409.	2.5	37
100	The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 32-40.	1.4	37
101	Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. <i>Clinical Cancer Research</i> , 2019, 25, 3962-3973.	7.0	36
102	Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 116-123.	1.4	36
103	Specimen Quality Evaluation in Canadian Biobanks Participating in the COEUR Repository. <i>Biopreservation and Biobanking</i> , 2013, 11, 83-93.	1.0	35
104	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. <i>British Journal of Cancer</i> , 2020, 123, 793-802.	6.4	35
105	Biomarker Expression in Pelvic High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2011, 30, 366-371.	1.4	34
106	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). <i>Gynecologic Oncology</i> , 2016, 141, 148-154.	1.4	34
107	High-grade Endometrioid Carcinoma of the Ovary. <i>American Journal of Surgical Pathology</i> , 2018, 42, 534-544.	3.7	34
108	Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 4309-4319.	7.0	33

#	ARTICLE	IF	CITATIONS
109	Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 252-262.	3.0	33
110	Implementation of a Canadian External Quality Assurance Program for Breast Cancer Biomarkers. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2009, 17, 375-382.	1.2	32
111	Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2017, 18, 515.	4.1	32
112	Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1187-1193.	2.5	31
113	Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 431-436.	2.5	29
114	Nuclear β -catenin and <i>CDX2</i> expression in ovarian endometrioid carcinoma identify patients with favourable outcome. <i>Histopathology</i> , 2019, 74, 452-462.	2.9	29
115	Histological and molecular diversity and heterogeneity of precancerous lesions associated with inflammatory bowel diseases. <i>Journal of Clinical Pathology</i> , 2020, 73, 391-402.	2.0	29
116	Regulation of cell growth and the expression of extracellular matrix proteins in colorectal adenocarcinoma: a fibroblast-tumor cell coculture model to study tumor-host interactions in vitro. <i>European Journal of Cell Biology</i> , 2003, 82, 1-8.	3.6	28
117	Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. <i>BMC Cancer</i> , 2013, 13, 28.	2.6	28
118	Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 209-221.	1.4	28
119	Activation of Mitogen-Activated Protein Kinase Is Required for Migration and Invasion of Placental Site Trophoblastic Tumor. <i>American Journal of Pathology</i> , 2005, 167, 879-885.	3.8	27
120	Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma. <i>Modern Pathology</i> , 2021, 34, 1008-1016.	5.5	27
121	A comparison of p53 and <i>WT1</i> immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. <i>Histopathology</i> , 2017, 71, 736-742.	2.9	27
122	Expression of lysophosphatidic acid acyltransferase beta (LPAAT- β) in ovarian carcinoma: correlation with tumour grading and prognosis. <i>British Journal of Cancer</i> , 2005, 92, 1729-1736.	6.4	25
123	Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 397-404.	1.4	25
124	Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. <i>Gynecologic Oncology</i> , 2016, 141, 559-563.	1.4	25
125	Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas. <i>Histopathology</i> , 2018, 73, 299-305.	2.9	25
126	Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 537-545.	1.4	25

#	ARTICLE	IF	CITATIONS
127	Interleukin-10 in serous ovarian carcinoma cell lines. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 328-333.	4.2	24
128	Genetic Variation in <i>TYMS</i> in the One-Carbon Transfer Pathway Is Associated with Ovarian Carcinoma Types in the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1822-1830.	2.5	24
129	PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma. <i>Gynecologic Oncology</i> , 2014, 132, 188-193.	1.4	24
130	Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma. <i>Histopathology</i> , 2017, 70, 347-358.	2.9	24
131	Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are Uncommon. <i>American Journal of Surgical Pathology</i> , 2019, 43, 531-537.	3.7	24
132	Overexpression of IGF2BP3 as a Potential Oncogene in Ovarian Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 1570.	2.8	24
133	A rare case of NUT midline carcinoma. <i>Gynecologic Oncology Case Reports</i> , 2013, 3, 1-3.	0.9	22
134	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	3.0	22
135	Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. <i>Clinical Cancer Research</i> , 2022, 28, 4947-4956.	7.0	22
136	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021, 34, 194-206.	5.5	21
137	Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues. <i>International Journal of Cancer</i> , 2007, 120, 2393-2400.	5.1	20
138	Tea, coffee, and caffeinated beverage consumption and risk of epithelial ovarian cancers. <i>Cancer Epidemiology</i> , 2016, 45, 119-125.	1.9	20
139	Adult lifetime alcohol consumption and invasive epithelial ovarian cancer risk in a population-based case-control study. <i>Gynecologic Oncology</i> , 2016, 140, 277-284.	1.4	20
140	Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles. <i>Cancer Causes and Control</i> , 2017, 28, 447-457.	1.8	20
141	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. <i>Cancer Causes and Control</i> , 2017, 28, 459-468.	1.8	20
142	The utility of color normalization for AI-based diagnosis of hematoxylin and eosin-stained pathology images. <i>Journal of Pathology</i> , 2022, 256, 15-24.	4.5	19
143	Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 157, 12-20.	1.4	18
144	Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells. <i>Cancer Letters</i> , 2003, 195, 101-109.	7.2	17

#	ARTICLE	IF	CITATIONS
145	Ovarian Endometrioid Carcinoma Misdiagnosed as Mucinous Carcinoma: An Underrecognized Problem. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 568-575.	1.4	17
146	p53 immunohistochemical analysis of fusion-positive uterine sarcomas. <i>Histopathology</i> , 2021, 78, 805-813.	2.9	17
147	A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5325.	4.1	16
148	Diagnosis of Ovarian Carcinoma Histotype Based on Limited Sampling. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 517-527.	1.4	15
149	PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer. <i>Gynecologic Oncology</i> , 2020, 158, 776-784.	1.4	15
150	Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 19-32.	3.0	15
151	Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. <i>Journal of Pathology</i> , 2022, 256, 388-401.	4.5	15
152	Napsin A. <i>American Journal of Clinical Pathology</i> , 2014, 142, 735-737.	0.7	14
153	You won't believe this old test that does cheap single-cell mutation detection. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 149-153.	3.0	14
154	PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin. , 2020, 8, e001128.		14
155	Letter in response to: McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. <i>J Pathol</i> 2018; 244: 538-549. <i>Journal of Pathology</i> , 2018, 245, 249-250.	4.5	13
156	Glucose transporter GLUT1 in colorectal adenocarcinoma cell lines is inversely correlated with tumour cell proliferation. <i>Anticancer Research</i> , 2005, 25, 3431-6.	1.1	13
157	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	2.5	12
158	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 132-141.	2.5	12
159	Molecular analysis suggests oligoclonality and metastasis of endometriosis lesions across anatomically defined subtypes. <i>Fertility and Sterility</i> , 2022, 118, 524-534.	1.0	12
160	A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 177-188.	3.0	11
161	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1470-1473.	2.5	10
162	Canadian Consensus-based and Evidence-based Guidelines for Benign Endometrial Pathology Reporting in Biopsy Material. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 119-127.	1.4	10

#	ARTICLE	IF	CITATIONS
163	Aberrantly Expressed Embryonic Protein NODAL Alters Breast Cancer Cell Susceptibility to β T Cell Cytotoxicity. <i>Frontiers in Immunology</i> , 2020, 11, 1287.	4.8	10
164	Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies. <i>International Journal of Gynecological Pathology</i> , 2022, 41, 12-19.	1.4	10
165	Loss of ARID1B and SMARCB1 expression are specific for the diagnosis of dedifferentiated/undifferentiated carcinoma in tumours of the upper gynaecological tract and cervix. <i>Histopathology</i> , 2021, 79, 160-167.	2.9	10
166	Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary. <i>Gynecologic Oncology</i> , 2021, 162, 421-430.	1.4	10
167	Accurate Distinction of Ovarian Clear Cell From Endometrioid Carcinoma Requires Integration of Phenotype, Immunohistochemical Predictions, and Genotype. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1452-1463.	3.7	10
168	Endometrial Stromal Sarcomas With BCOR Internal Tandem Duplication and Variant BCOR/BCORL1 Rearrangements Resemble High-grade Endometrial Stromal Sarcomas With Recurrent CDK4 Pathway Alterations and MDM2 Amplifications. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1142-1152.	3.7	10
169	FIGO Stage Is the Strongest Prognostic Factor in Adenocarcinoma of the Uterine Cervix. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019, 41, 1318-1324.	0.7	9
170	Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes. <i>Gynecologic Oncology</i> , 2020, 157, 36-45.	1.4	9
171	Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2022, 41, 168-179.	1.4	9
172	Biobanking in the Twenty-First Century: Driving Population Metrics into Biobanking Quality. <i>Advances in Experimental Medicine and Biology</i> , 2015, 864, 95-114.	1.6	9
173	Cellular context determines DNA methylation profiles in SWI/SNF-deficient cancers of the gynecologic tract. <i>Journal of Pathology</i> , 2022, 257, 140-145.	4.5	9
174	Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression. <i>Npj Precision Oncology</i> , 2022, 6, .	5.4	9
175	Dicer and Drosha in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2009, 360, 1150-1151.	27.0	8
176	Differentially Methylated Loci Distinguish Ovarian Carcinoma Histological Types: Evaluation of a DNA Methylation Assay in FFPE Tissue. <i>BioMed Research International</i> , 2013, 2013, 1-11.	1.9	8
177	Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk. <i>British Journal of Cancer</i> , 2017, 116, 265-269.	6.4	8
178	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 855-871.	2.8	8
179	Newly recognized non-adenomatous lesions associated with enteric carcinomas in inflammatory bowel disease – Report of six rare and unique cases. <i>Annals of Diagnostic Pathology</i> , 2020, 44, 151455.	1.3	7
180	High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy. <i>Human Pathology</i> , 2020, 98, 56-63.	2.0	7

#	ARTICLE	IF	CITATIONS
181	Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. <i>British Journal of Cancer</i> , 2021, 125, 265-276.	6.4	7
182	Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status. <i>Gynecologic Oncology</i> , 2021, 161, 342-346.	1.4	7
183	Influence of Various Cytokines on Adhesion and Migration of the Colorectal Adenocarcinoma Cell Line HRT-18. <i>Oncology</i> , 2005, 68, 33-39.	1.9	6
184	Letter to the editor regarding Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression. <i>Modern Pathology</i> , 2011, 24, 1281-1282.	5.5	6
185	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. <i>Carcinogenesis</i> , 2021, 42, 785-793.	2.8	6
186	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. <i>Human Genetics and Genomics Advances</i> , 2021, 2, 100042.	1.7	6
187	Endometrial neuroendocrine carcinoma and undifferentiated carcinoma are distinct entities with overlap in neuroendocrine marker expression. <i>Histopathology</i> , 2022, 81, 44-54.	2.9	6
188	Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (<sc>COSP</sc>) is a reliable high-throughput tool for case review. <i>Histopathology</i> , 2013, 63, 704-712.	2.9	5
189	Treatment and outcomes in undifferentiated and dedifferentiated endometrial carcinoma. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	5
190	Type-Specific Response to Neoadjuvant Chemotherapy: Ovarian High-Grade Serous Carcinoma Versus Colorectal Mucinous Carcinoma. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2012, 34, 678-682.	0.7	4
191	Synchronous Ovarian and Appendiceal Mucinous Neoplasms in the Absence of Pseudomyxoma Peritonei. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 214-222.	2.5	4
192	Cervical Adenocarcinoma: A Comparison of the Reproducibility of the World Health Organization 2003 and 2014 Classifications. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 132-138.	1.9	4
193	Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa. <i>Modern Pathology</i> , 2020, 33, 2361-2377.	5.5	4
194	Prognostic value of progesterone receptor expression in tubo-ovarian high-grade serous carcinoma of the <sc>COEUR</sc> cohort. <i>Histopathology</i> , 2019, 74, 663-666.	2.9	3
195	Ovarian cancer: diagnostic accuracy and tumor types distribution in East Africa compared to North America. <i>Diagnostic Pathology</i> , 2020, 15, 86.	2.0	3
196	Embryonic protein NODAL regulates the breast tumor microenvironment by reprogramming cancer-derived secretomes. <i>Neoplasia</i> , 2021, 23, 375-390.	5.3	3
197	Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas. <i>Current Drug Targets</i> , 2020, 21, 974-995.	2.1	3
198	Dedifferentiation in Breast Metastasis of Endometrial Carcinoma: A Diagnostic Dilemma. <i>International Journal of Gynecological Pathology</i> , 2022, 41, 35-39.	1.4	2

#	ARTICLE	IF	CITATIONS
199	Abstract 1535: Immunohistochemistry predicts presence and type of TP53 mutation in high-grade serous carcinoma. <i>Cancer Research</i> , 2014, 74, 1535-1535.	0.9	2
200	Molecular Pathology of Ovarian Carcinomas. <i>Surgical Pathology Clinics</i> , 2011, 4, 275-296.	1.7	1
201	Re: Biopreserv Biobank 11:83-93. <i>Biopreservation and Biobanking</i> , 2013, 11, 257-257.	1.0	1
202	New Views of Ovarian Carcinoma Types: How Will This Change Practice?. , 2014, , 29-38.		1
203	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line. <i>PLoS ONE</i> , 2020, 15, e0240412.	2.5	1
204	Adenocarcinoma of the Uterine Cervix: Immunohistochemical Biomarker Expression and Diagnostic Performance. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 209-217.	1.2	1
205	Tumor Type and Substage Predict Survival in Stage I and II Ovarian Carcinoma: Insights and Implications. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 232-234.	0.4	0
206	Re. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 176.	1.4	0
207	Disseminated <i>Mycobacterium kansasii</i> Infection in a Patient With Silicosis, Pulmonary Alveolar Proteinosis, and Myelodysplastic Syndrome. <i>Chest</i> , 2015, 148, 154A.	0.8	0
208	Genomic Applications in Ovarian Cancer. , 2019, , 471-482.		0
209	The MOCOG study: Learning from extraordinary responders to improve treatment outcomes for women with ovarian cancer. <i>Pathology</i> , 2020, 52, S30-S31.	0.6	0
210	Low-Grade Serous Carcinoma - The Clinical Challenge. <i>Gynecology and Obstetrics Research: Open Journal</i> , 2015, 2, 35-40.	1.6	0
211	Protracted clinical course of an AFF1 fusion positive uterine smooth muscle tumor causing diagnostic confusion over a course of 15 years. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100890.	0.6	0
212	Testing Algorithms for the Diagnosis of Malignant Glandular Tumors of the Uterine Cervix Histotyped per the International Endocervical Adenocarcinoma Criteria and Classification (IECC) System. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, Publish Ahead of Print, .	1.2	0
213	Title is missing!. , 2020, 15, e0240412.		0
214	Title is missing!. , 2020, 15, e0240412.		0
215	Title is missing!. , 2020, 15, e0240412.		0
216	Title is missing!. , 2020, 15, e0240412.		0